Navigation Links
R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
Date:7/21/2009

mit at any of the prescribed time points. In the 5-day repeated-dose study, in the morning and at night 2 ml of RK-023 preparation or 2 ml of placebo was applied to 6 and 2 out of 8 healthy adult males respectively. No serious adverse event was observed during the total 9 times of application up to the morning of day 5. When the drug concentration in the blood was measured, the level was below the quantification limit as in the case of the single-dose study.

As described above, percutaneous absorption of the drug was not high even after continuous application in the morning and at night for 5 days, suggesting hardly any safety problem.

Yukihiko Mashima, Representative Director and President of R-Tech Ueno, commented as follows. "We are pleased to announce the successful completion of a phase 1 clinical study on our self-developed RK-023 that focuses on the dermatology field. We intend to start a phase 2 clinical study in Japan as scheduled and at the same time proceed with full-scale negotiations for partnership at home and abroad."

Having obtained the results of the above-mentioned phase 1 clinical study, we plan to promptly conduct a phase 2 clinical study and accelerate our efforts to develop a drug that will become useful for the patients with androgenetic alopecia as soon as possible.

Note: Androgenetic alopecia:

Due to the influence of male hormones during and after puberty, thick and long hair does not regenerate but is replaced with thin and short soft hair, and consequently the hair follicles become atrophied, reducing the quantity of hair, localized from the parietal to the frontal region.

*About R-Tech Ueno, Ltd.

R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Led by Dr. Yukihiko Mashima, Representative Director and President of R-Tech Ueno, this pharmaceutical venture enterprise has
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
4. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
7. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
8. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... LOS ANGELES , Oct. 30, 2014 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... technology and its lead drug candidate, aldoxorubicin.  The ... A New Approach," will be given by ... the Sarcoma Oncology Center and principal investigator of ...
(Date:10/30/2014)... October 30, 2014 ... beim Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie ... bei Säuglingen und Kleinkindern. Der bisher übliche ... Ernährung der Babys bzw. deren stillenden Mütter ... dass sich bei einer beträchtlichen Anzahl von ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... -- ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" ... research and development outsourcing company, today announced that it ... in its biologics division, which portends strong growth for ... milestones were achieved for two oncology projects that are ...
... WuXi PharmaTech (Cayman) Inc. (NYSE: ... the pharmaceutical, biotechnology, and medical device industries, with operations in ... for the second quarter of 2011. Highlights ... Million for the First Time Second-Quarter 2011 Net ...
Cached Medicine Technology:ShangPharma's Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects 2WuXi PharmaTech Announces Second Quarter 2011 Results 2WuXi PharmaTech Announces Second Quarter 2011 Results 3WuXi PharmaTech Announces Second Quarter 2011 Results 4WuXi PharmaTech Announces Second Quarter 2011 Results 5WuXi PharmaTech Announces Second Quarter 2011 Results 6WuXi PharmaTech Announces Second Quarter 2011 Results 7WuXi PharmaTech Announces Second Quarter 2011 Results 8WuXi PharmaTech Announces Second Quarter 2011 Results 9WuXi PharmaTech Announces Second Quarter 2011 Results 10WuXi PharmaTech Announces Second Quarter 2011 Results 11WuXi PharmaTech Announces Second Quarter 2011 Results 12WuXi PharmaTech Announces Second Quarter 2011 Results 13WuXi PharmaTech Announces Second Quarter 2011 Results 14WuXi PharmaTech Announces Second Quarter 2011 Results 15WuXi PharmaTech Announces Second Quarter 2011 Results 16WuXi PharmaTech Announces Second Quarter 2011 Results 17
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... News) -- When it comes to heart disease, a new ... care when they have symptoms that spell trouble. "The ... with a more severe or advanced stage of heart disease, ... Kreatsoulas, a Fulbright Scholar and research fellow at the Harvard ... the Heart and Stroke Foundation of Canada. In the ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... lots of milk could be bad for your health, a ... calcium in milk can help strengthen bones and prevent osteoporosis. ... to recommend milk as part of a healthy diet. ... milk did not protect men or women from bone fractures, ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Americans, opinions about ... lines, a new study finds. Democratic voters are ... according to the researchers. Almost three-quarters of Democrats want ... Thirty percent want Congress to implement the current law, ... the ACA. Among Independent voters, one-third want the ...
(Date:10/30/2014)... 29, 2014) – A new standard of care for ... following a multi-year study published in the latest edition ... , The research, led by John Wagner, Jr., M.D., ... at the University of Minnesota and a researcher in ... in children with acute leukemia and myelodysplastic syndrome who ...
Breaking Medicine News(10 mins):Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3
... Southwestern Medical Center maternal-fetal specialists have confirmed a potential ... risk for hepatitis B, a health problem that affects ... vaccination schedule for high-risk pregnant women was found effective ... Obstetrics & Gynecology . While the normal three-shot ...
... , MONDAY, June 27 (HealthDay News) -- Certain groups ... poorer outcomes and higher death rates than those treated ... study. Nearly five million people live in U.S. ... Northern Mariana Islands and the U.S. Virgin Islands, according ...
... childhood cancer survivors found that the first cancer is ... forms of the disease for about 10 percent of ... in the federally funded Childhood Cancer Survivor Study (CCSS). ... reported that 1,382, or 9.6 percent, of survivors developed ...
... 27 (HealthDay News) -- Uncovering some science behind the type ... and Canadian researchers reports that a woman can tell whether ... face when she is ovulating. Women also appear to ... they start to harbor romantic notions or mating aspirations, the ...
... Scientists have long known that, to form tissue structures ... the other cells, matrix, and signals in their environment. But ... to distinguish between normal and pathological behaviors. A team of ... to evaluate human stem cells using cell micropatterning a ...
... HealthDay Reporter , MONDAY, June 27 (HealthDay News) -- ... both by violent media content and greater evening use of ... Reviewing parent surveys and media diaries from 617 preschoolers, Seattle ... was linked to a significant jump in sleep problems, as ...
Cached Medicine News:Health News:Stepped-up vaccine series for hepatitis B is effective during pregnancy 2Health News:Childhood cancer survivors are at high risk for multiple tumors as they age 2Health News:Childhood cancer survivors are at high risk for multiple tumors as they age 3Health News:Does Ovulation Boost a Woman's 'Gaydar'? 2Health News:Tiny cell patterns reveal the progression of development and disease 2Health News:Tiny cell patterns reveal the progression of development and disease 3Health News:Content, Timing of TV Can Take Toll on Kids' Sleep 2Health News:Content, Timing of TV Can Take Toll on Kids' Sleep 3
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Straight shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: